<?xml version="1.1" encoding="UTF-8" standalone="yes"?><xml><head><creation_date>D:20110825152619+02'00'</creation_date><modification_date>D:20110825152622+02'00'</modification_date><initial_authorization>False</initial_authorization><pdf_file>EU-1-04-283_h_w_dec_19.pdf</pdf_file></head><body><section><header>european commission brussels, 18.8.2011 c(2011)6053 final</header></section><section><header>commission implementing decision of 18.8.2011 
 amending the marketing authorisation granted by decision c(2004)3160 for “ariclaim -
 duloxetine hydrochloride”, a medicinal product for human use</header><p>(text with eea relevance) (only the dutch text is authentic)</p></section><section><header>commission implementing decision of 18.8.2011 
 amending the marketing authorisation granted by decision c(2004)3160 for 
 “ariclaim - duloxetine hydrochloride”, a medicinal product for human use</header><p>(text with eea relevance) (only the dutch text is authentic) 
 the european commission, 
 having regard to the treaty on the functioning of the european union, 
 having regard to regulation (ec) no 726/2004 of the european parliament and of the 
 council of 31 march 2004 laying down community procedures for the authorisation and 
 supervision of medicinal products for human and veterinary use and establishing a 
 european medicines agency
 1, having regard to commission regulation (ec) no 1234/2008 of 24 november 2008 
 concerning the examination of variations to the terms of marketing authorisations for 
 medicinal products for human use and veterinary medicinal products
 2, and in particular article 20(7)(a) thereof, 
 having regard to the application submitted on 24 april 2011 by eli lilly nederland b.v. 
 under article 20(3) of regulation (ec) no 1234/2008, 
 having regard to the opinion of the european medicines agency, formulated on 23 june 
 2011 by the committee for medicinal products for human use, 
 whereas: 
 (1)</p><p>the european medicines agency has informed the marketing authorisation 
 holder and the commission of its favourable opinion on the major variation type 
 ii and of the need to amend the marketing authorisation for the medicinal product 
 &quot;ariclaim - duloxetine hydrochloride&quot; which is entered in the community 
 register of medicinal products under numbers eu/1/04/283/008-012.</p><p>
 1 oj l 136, 30.4.2004, p. 1. 2 oj l 334, 12.12.2008, p. 7.</p><p> (2) the marketing authorisation should be updated and decision c(2004)3160 of 11 
 august 2004 should therefore be amended accordingly. the community register 
 of medicinal products should also be updated. 
 (3)</p><p>for the sake of clarity and transparency, it is appropriate, following the 
 amendment of part or parts of the annexes, to provide for a consolidated version 
 thereof. the annexes to decision c(2004)3160 should therefore be replaced, 
 has adopted this decision: 
 article 1 decision c(2004)3160 is amended as follows:</p><p>1) annex i is replaced by the text set out in annex i to this decision;</p><p>2) annex iii b is replaced by the text set out in annex iii b to this decision. 
 article 2 this decision is addressed to eli lilly nederland b.v., grootslag 1-5, 3991 ra houten, nederland. 
 done at brussels, on 18.8.2011.</p><p>for the commission</p><p>
 paola testori coggi</p><p>
 director-general</p></section></body></xml>